SIP
RPRX

Stoneridge Investment Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

Stoneridge Investment Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-13,377
Closed -$247K – 263
2013
Q2 		$247K Buy
+13,377
New +$236K 0.06% 156

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stoneridge Investment Partners's RPRX Position: Q3 2013 in Review

Stoneridge Investment Partners sold out of Repros Therapeutics Inc. (RPRX) in Q3 2013, closing a stake of 13,377 shares — an estimated $247K sold.

Stoneridge Investment Partners first reported a position in RPRX in Q2 2013 and held it in 1 quarter. The position peaked at $247K in Q2 2013. 92 funds tracked by Wall St. Rank hold RPRX as of Q3 2013.

  • Stoneridge Investment Partners reported no remaining Repros Therapeutics Inc. position as of Q3 2013 after selling out during the quarter.
  • Stoneridge Investment Partners sold 13,377 Repros Therapeutics Inc. shares in Q3 2013, an estimated $247K.
  • Stoneridge Investment Partners first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 1 quarter.
  • Stoneridge Investment Partners's Repros Therapeutics Inc. position peaked at $247K in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2013.

Based on Stoneridge Investment Partners's 13F filing for Q3 2013, filed 15 Oct 2013.